Development of a Low-Profile Dual Hormone Patch Pump with Novel Occlusion Sensor

一种低调双激素贴片泵的研制 带有新型遮挡传感器 项目总结： 该项目的具体目标是开发一种离散的、低调的、双激素药物。 采用SFC Fluidics的微流控技术的输送系统。DualPump™将是 开发的一个专有ePump®机身将独立而准确地提供 胰岛素和胰升糖素来自两个不同的储存库。将独立锁紧安全阀组 并安全地控制每种激素的传递，分配确认传感器将通知 因堵塞或电气/机械故障而导致的任何给药错误的使用者。阶段 II将看到所有组件集成到一个精确、离散、低调的可穿戴吊舱中， 在猪身上进行广泛的台式测试和初步测试。第二阶段的最终目标是生产 已引入FDA的DualPump模块，可与 双激素人工胰腺所需的其他组件。在第二阶段，证监会 流体公司将与连续血糖监测仪、控制算法和 稳定的药物配方，开发FDA批准的、强健和可靠的双重激素 人工胰腺。

Development of a Low-Profile Dual Hormone Patch Pump with Novel Occlusion Sensor Project Summary: The Specific Aim of this project is to develop a discrete, low-profile, dual hormone drug delivery system using SFC Fluidics’ enabling microfluidic technologies. A DualPump™ will be developed in which one proprietary ePump® body will independently and accurately deliver both insulin and glucagon from two separate reservoirs. Latching safety valve sets will independently and safely control the delivery of each hormone and a dispense confirmation sensor will notify the user of any dosing errors resulting from occlusions or electrical/mechanical failures. Phase II will see the integration of all components into an accurate, discrete, low-profile wearable pod, extensive benchtop testing and initial testing in swine. The end goal of Phase II is production of a DualPump module that has been introduced to the FDA and is ready to be integrated with all other components required for a dual hormone artificial pancreas. During Phase IIB, SFC Fluidics will work with manufacturers of continuous glucose monitors, control algorithms and stable drug formulations to develop an FDA-approved, robust, and reliable dual hormone artificial pancreas.